The field of cancer immunology has undergone significant transformation over the past decade, reshaping our understanding of tumor–immune system ...

Researchers have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects. By applying brief, localized pulses of magnetic fields, the team ...

Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in ...

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating ...

British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients Novocure (NASDAQ: NVCR) announced today that the province of British ...